Antidementia Medications: Pharmacology and Biochemistry

[1]  P. Rossini,et al.  Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®) , 2021, Pharmaceuticals.

[2]  A. Brickman,et al.  Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis , 2021, BMJ.

[3]  C. Tiu,et al.  Effectiveness and Safety Profile of Ginkgo Biloba Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment. , 2021, CNS & neurological disorders drug targets.

[4]  R. Ihl,et al.  Strategies for the use of Ginkgo biloba extract, EGb 761®, in the treatment and management of mild cognitive impairment in Asia: Expert consensus , 2020, CNS neuroscience & therapeutics.

[5]  O. Wirths,et al.  Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer’s Disease , 2020, Molecular Neurobiology.

[6]  M. Mattson,et al.  Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing , 2020, Nature Reviews Drug Discovery.

[7]  J. Hort,et al.  Management of mild cognitive impairment (MCI): The need for national and international guidelines , 2020, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[8]  J. Fessel.  The potential for one drug, administered at the earliest preclinical stage, to prevent the subsequent decline of cognition that eventuates in dementia , 2020, Alzheimer's & dementia.

[9]  David A Bennett,et al.  Diagnosis and Management of Dementia: Review. , 2019, JAMA.

[10]  H. Möller,et al.  Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer’s disease , 2019, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[11]  J. Fessel.  Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs , 2019, Alzheimer's & dementia.

[12]  B. Vissel,et al.  Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease , 2018, Acta Neuropathologica.

[13]  M. Mesulam,et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.

[14]  A. von Gunten,et al.  Efficacy of Ginkgo biloba extract EGb 761® in dementia with behavioural and psychological symptoms: A systematic review , 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[15]  A. Grimm,et al.  Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer’s disease , 2015, Biogerontology.

[16]  L. Rashed,et al.  Modification of Hippocampal Markers of Synaptic Plasticity by Memantine in Animal Models of Acute and Repeated Restraint Stress: Implications for Memory and Behavior , 2015, NeuroMolecular Medicine.

[17]  R. Swerdlow,et al.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. , 2014, Biochimica et biophysica acta.

[18]  Muriel Noetzli,et al.  Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease , 2013, Clinical Pharmacokinetics.

[19]  G. Koch,et al.  Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease? , 2010, CNS neuroscience & therapeutics.

[20]  J. Orgogozo,et al.  Improved Mitochondrial Function in Brain Aging and Alzheimer Disease – the New Mechanism of Action of the Old Metabolic Enhancer Piracetam , 2010, Front. Neurosci..

[21]  S. Willich,et al.  Effects of Ginkgo biloba in dementia: systematic review and meta-analysis , 2010, BMC geriatrics.

[22]  H. Qi,et al.  Effectiveness of standardized ginkgo biloba extract on cognitive symptoms of dementia with a six-month treatment: a bivariate random effect meta-analysis. , 2010, Pharmacopsychiatry.

[23]  B. Winblad,et al.  Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis , 2002, Dementia and Geriatric Cognitive Disorders.

[24]  P. Riederer,et al.  Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia , 1995, Pharmacopsychiatry.

[25]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[26]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .